| Literature DB >> 25145350 |
Matthieu Fisichella, Frederic Berenguer, Gerard Steinmetz, Melanie Auffan, Jerome Rose, Odette Prat1.
Abstract
BACKGROUND: Engineered nanomaterials may release nanosized residues, by degradation, throughout their life cycle. These residues may be a threat for living organisms. They may be ingested by humans through food and water. Although the toxicity of pristine CeO2 nanoparticles (NPs) has been documented, there is a lack of studies on manufactured nanoparticles, which are often surface modified. Here, we investigated the potential adverse effects of CeO2 Nanobyk 3810™ NPs, used in wood care, and their residues, altered by light or acid.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25145350 PMCID: PMC4150968 DOI: 10.1186/1471-2164-15-700
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1High-Resolution Transmission Electron Microscope images of CeO NPs and Nanobyk™ NPs in deionized water. A) uncoated CeO2 NPs, B) NB NPs before treatment, C) NB NPs after 4 months aging in daylight (NB-DL), and D) NB NPs after acidic degradation (NB-DA). The inter-reticular distance (dhkl) measured at ~3.2 Å is attributed to the (111) crystalline plane of CeO2. No changes in shape, crystal structure, or CeO2 cluster size were observed by HRTEM.
Figure 2Caco-2 cell viability tests. Caco-2 cells were grown in 96-well plates and differentiated for 21 days. Cells were then exposed for 24 h or 72 h to concentrations of CeO2 NPs ranging from 21.25 to 170 μg/mL. Left side) ATP tests: cell viability was determined by reading the level of bioluminescence (CellTiter-Glo luminescent cell viability assay, Promega). Right side) XTT tests: cell viability was determined by mitochondrial enzyme activity via XTT reagent (In Vitro toxicology assay kit XTT based, Sigma-Aldrich). An experimental positive control was obtained by exposing cells to H2O2 in both tests. Cell viability was not altered for concentrations up to 170 mg/L.
Figure 3SEM image and cerium characterization. Left side: SEM image, obtained in BSE mode, of Caco-2 cells exposed to Nanobyk-DL. Magnification 500 x. Right side: The EDX spectrum of the clear spots detected on the cell membrane indicates they are composed of cerium.
Microarray results
| Microarray Analyses | Number of detected genes | Number of genes up/down- regulated (>1.5 fold change ) | Number of genes significantly up/ down- regulated (pvalue < 0.05) | % of genes altered out of detected spots |
|---|---|---|---|---|
| CTRL 2 vs. CTRL 1 | 23425 | 970 | 5 | 0.02% |
| NB vs. CTRL 1 | 33312 | 1036 | 13 | 0.04% |
| NB-DL vs. CTRL 1 | 23962 | 1773 | 344 | 1.44% |
| NB-DA vs. CTRL 2 | 22892 | 2079 | 428 | 1.87% |
| Pristine CeO2 vs. CTRL 3 | 33023 | 6020 | 1643 | 4.98% |
| H2O2 vs. CTRL 3 | 28900 | 14651 | 9307 | 32.2% |
Caco-2 cells were cultured and differentiated for 21 days. The cells were exposed for 72 h to 21.25 μg/mL CeO2 NPs, surface-treated or degraded (n = 2). Pristine CeO2 NPs at the same concentration and H2O2 (20 μM) were used as positive controls. After mRNA extraction, labeled cDNA (Cy3) was hybridized (n = 4) to an Agilent oligomicroarray (4 × 44,000 probes). The number of genes detected above the signal threshold was compared for each type of NP versus their own control. From these remaining spots, we selected those with fluorescence ratios (representing NP-treated samples versus untreated samples) above 1.5-fold change. Out of these spots, we selected those satisfying Benjamini-Hochberg multiple testing corrections. At the end of this analysis, we obtained lists of genes that were significantly induced or repressed after exposure to NPs.
Figure 4Radar plots of gene distribution per altered function. Genes significantly induced or repressed after exposure to NPs were selected as described in Table 1, Column 4. Genes were selected with fold-change ratios greater than 1.5 (n = 4, p-value ≤ 0.05), and distributed per function. This graph displays the number of significantly altered genes per function. The enlarged part concerns light-degraded Nanobyk (NB-DL) and acid-degraded Nanobyk (NB-DA). For each compound, a pattern is obtained representing the amplitude and the nature of its toxicity, then allowing a visual comparison of their respective toxicities.
Figure 5Comparative analysis of significantly altered pathways by CeO NPs (dark blue), NB-DL NPs (medium blue) and NB-DA NPs (light blue). The y-axis depicts genes ratio within a dataset mapping to the considered pathway (see Methods for calculation). A fisher’s exact test was used to determine a p-value representing the significance of these associations (p < 0.01).
Lists of genes significantly altered by exposure to pristine CeO (Part A), NB-DA (Part B) and NB-DL (Part C), and belonging to the canonical pathway “mitochondrial dysfunction”
| Part A: genes altered by pristine CeO2 (n = 27) | ||||
|---|---|---|---|---|
| Symbol | Entrez Gene Name | Fold Change | p-value | ID Agilent |
| ATP5J | ATP synthase, H + transporting, mitochondrial F0 complex, subunit F6 | −1,935 | 8,67E-03 | A_23_P154832 |
| COX4I1 | cytochrome c oxidase subunit IV isoform 1 | −2,313 | 4,97E-03 | A_23_P141029 |
| COX5B | cytochrome c oxidase subunit Vb | −2,312 | 4,98E-03 | A_23_P51069 |
| COX6A1 | cytochrome c oxidase subunit VIa polypeptide 1 | −2,312 | 4,99E-03 | A_32_P168247 |
| COX6B1 | cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) | −2,306 | 4,87E-03 | A_23_P108244 |
| COX6C | cytochrome c oxidase subunit VIc | −2,088 | 3,08E-03 | A_23_P8900 |
| COX7A2 | cytochrome c oxidase subunit VIIa polypeptide 2 (liver) | −2,311 | 4,99E-03 | A_23_P81690 |
| COX7C | cytochrome c oxidase subunit VIIc | −2,312 | 4,99E-03 | A_23_P110811 |
| COX8A | cytochrome c oxidase subunit 8A (ubiquitous) | −2,312 | 5,00E-03 | A_23_P52639 |
| CYB5R3 | cytochrome b5 reductase 3 | −2,312 | 4,99E-03 | A_23_P502224 |
| NDUFA3 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9 kDa | −2,052 | 4,57E-03 | A_23_P208540 |
| NDUFA4 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDa | −2,312 | 4,98E-03 | A_23_P145777 |
| NDUFA6 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa | −2,037 | 6,10E-03 | A_23_P91769 |
| NDUFA8 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19 kDa | −2,200 | 4,97E-03 | A_23_P43566 |
| NDUFB2 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa | −2,175 | 2,93E-03 | A_24_P406301 |
| NDUFB4 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15 kDa | −2,301 | 4,77E-03 | A_23_P69468 |
| NDUFB8 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19 kDa | −1,963 | 4,31E-03 | A_24_P346886 |
| NDUFB9 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22 kDa | −2,311 | 4,99E-03 | A_23_P157669 |
| NDUFS2 | NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49 kDa (NADH-coenzyme Q reductase) | −1,561 | 5,68E-04 | A_23_P149470 |
| NDUFS5 | NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15 kDa (NADH-coenzyme Q reductase) | −2,311 | 4,98E-03 | A_23_P10463 |
| NDUFS7 | NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20 kDa (NADH-coenzyme Q reductase) | −2,079 | 3,89E-03 | A_23_P165086 |
| NDUFS8 | NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23 kDa (NADH-coenzyme Q reductase) | −1,904 | 7,63E-03 | A_23_P86774 |
| NDUFV1 | NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa | −1,704 | 1,08E-02 | A_23_P127353 |
| OGDH | oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) | −1,513 | 3,02E-03 | A_23_P123133 |
| PRDX5 | peroxiredoxin 5 | −1,946 | 5,32E-03 | A_24_P155378 |
| UQCRFS1 | ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | −2,031 | 3,93E-03 | A_23_P153586 |
| UQCRH | ubiquinol-cytochrome c reductase hinge protein | −2,312 | 4,99E-03 | A_32_P54137 |
|
| ||||
| Symbol | Entrez Gene Name | Fold Change | p-value | ID Agilent |
| ATP5B | ATP synthase, H + transporting, mitochondrial F1 complex, beta polypeptide | −1,575 | 2,48E-02 | A_23_P33216 |
| ATP5C1 | ATP synthase, H + transporting, mitochondrial F1 complex, gamma polypeptide 1 | −1,525 | 3,84E-02 | A_23_P63655 |
| COX6A2 | cytochrome c oxidase subunit VIa polypeptide 2 | −2,028 | 4,43E-02 | A_23_P401524 |
| COX6B2 | cytochrome c oxidase subunit VIb polypeptide 2 (testis) | −1,522 | 2,45E-02 | A_23_P78571 |
| CYCS | cytochrome c, somatic | −1,674 | 3,09E-02 | A_24_P376556 |
| NDUFA5 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13 kDa | −1,815 | 2,45E-02 | A_32_P96641 |
| PRDX3 | peroxiredoxin 3 | −2,65 | 2,51E-02 | A_23_P63751 |
| PSEN2 | presenilin 2 (Alzheimer disease 4) | −1,647 | 2,98E-02 | A_23_P96985 |
| SDHB | succinate dehydrogenase complex, subunit B, iron sulfur (Ip) | −1,646 | 2,46E-02 | A_23_P149649 |
| SDHD | succinate dehydrogenase complex, subunit D, integral membrane protein | −1,841 | 2,39E-02 | A_23_P138967 |
|
| ||||
| Symbol | Entrez Gene Name | Fold Change | p-value | ID Agilent |
| COX11 | COX11 cytochrome c oxidase assembly homolog (yeast) | −1,723 | 3,28E-02 | A_24_P404204 |
| SDHC | succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa | −2,264 | 3,53E-02 | A_24_P233850 |
| SDHD | succinate dehydrogenase complex, subunit D, integral membrane protein | −2,03 | 4,62E-02 | A_32_P60185 |
Although the same pathway is activated, there are, stricto sensu, no common genes altered by pristine CeO2 and NB-DA or NB-DL in the mitochondrial dysfunction pathway. This demonstrates the interest of a pathway-driven analysis compared to the usual gene-driven analysis.
Microarray gene expression validation
| Gene ID | Primers (5′-3′) | Microarray Fold change CeO 2/Ctrl | qRT-PCR Fold Change CeO 2/Ctrl |
|---|---|---|---|
|
| F:GTCAGCCGTCTCAGTCCATT | −1.94 | −1.75 |
| R:AAAAGCTCCCTCTCCAGCTC | |||
|
| F:TCCAGATGTTTGTTGGGACA | −2.31 | −5.52 |
| R:GTGGAAAATTGTGCGGATGT | |||
|
| F:CGCAAGGTCTACGACCAGAT | −1.68 | −2.39 |
| R:TCCCGCTTGATCTTCCTCT | |||
|
| F:GTGGTGGCCTGTCTGAGTGT | −1.95 | −1.74 |
| R:ATGCCATCCTGTACCACCAT | |||
|
|
|
|
|
|
| F:GTTGTCGCAGTCTCAGTGGA R:GACGCTCAAATGCTTGATGA | −2.65 | −2.98 |
|
| F:GTATGCCTCTTTGCCTCTGC R:GAGGCAACCCCATTAACTCA | −1.84 | −4.45 |
|
| F:CTACCAACACCTCCGCATC R:TCGAAGCTTCACACCTTTATTG | −2.03 | −2.08 |
|
|
|
|
|
|
| F:TTGAGTGCAGGGGTCTCTCT R:AACCAGGACAACCACTCCAG | −2.26 | −16.30 |
|
| F:GTATGCCTCTTTGCCTCTGC R:GAGGCAACCCCATTAACTCA | −2.03 | −22.10 |
F = forward; R = reverse.
Figure 6Complexes of the respiratory chain altered by degraded Nanobyk. Pristine CeO2 under-expressed 27 genes encoding subunits of complex I, III ( cytochrome b-c1), IV and V. Acid-degraded Nanobyk downregulated 10 genes encoding subunits of complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), complex IV (cytochrome c oxidase) and complex V (ATP synthase). Light-degraded Nanobyk down regulated 3 genes encoding subunits of complexes II and IV. Nanobyk NPs did not alter the respiratory chain. Differentially expressed genes belonging to this specific pathway are listed in Table 2.